D. Boral Capital Reiterates “Buy” Rating for Artelo Biosciences (NASDAQ:ARTL)

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $6.00 price objective on the stock. D. Boral Capital’s target price suggests a potential upside of 426.32% from the company’s current price.

A number of other analysts have also recently weighed in on ARTL. LADENBURG THALM/SH SH upgraded shares of Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a report on Tuesday, October 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Artelo Biosciences in a report on Monday, December 9th.

Artelo Biosciences Price Performance

Shares of NASDAQ:ARTL opened at $1.14 on Tuesday. The stock has a market cap of $3.68 million, a price-to-earnings ratio of -0.40 and a beta of 1.25. Artelo Biosciences has a 12 month low of $0.91 and a 12 month high of $1.75. The stock’s 50 day moving average price is $1.10 and its 200 day moving average price is $1.19.

Artelo Biosciences (NASDAQ:ARTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. On average, sell-side analysts expect that Artelo Biosciences will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.